Methylnaltexone demonstrated efficacious in reversing constipation for patients on chronic opioid therapy. It is a unique compound which does not cross into the brain, yet it can block opioid receptors outside the brain. Overview provides a brief history of the compound and our research to date. Publications lists work done on MNTX at the University of Chicago as well as other key references.
News covers recent developments.
Contact Info lists the names and addresses of the principle investigators on the project. These pages are provided for informational purposes only.